On October 20, 2025, RAPT Therapeutics, Inc. (Nasdaq: RAPT) and Shanghai Jeyou Pharmaceutical Co., Ltd. announced that the Phase 2 trial of RPT904 (JYB1904) in chronic spontaneous urticaria (CSU) produced positive topline data. The study, conducted in China, enrolled 137 adult patients and compared RPT904 at 8‑week (Q8W) and 12‑week (Q12W) dosing schedules to the standard 4‑week (Q4W) dosing of omalizumab.
The results showed that both Q8W and Q12W dosing of RPT904 achieved efficacy and safety profiles comparable to omalizumab, with no serious adverse events related to the study drug. The data also demonstrated a durable effect, with sustained free‑IgE reduction and clinical benefit observed up to week 16 after a single dose of RPT904. These findings suggest that RPT904 may offer a longer dosing interval while maintaining therapeutic efficacy.
Based on the positive data, Jeyou plans to advance RPT904 to a Phase 3 development program in China, and RAPT will discuss a Phase 3 development path with the U.S. Food and Drug Administration. RAPT also scheduled a webcast conference call at 8:30 a.m. ET on the same day to present the data and answer investor questions. The announcement signals a significant step forward in RAPT’s lead candidate pipeline and sets the stage for potential regulatory engagement and future clinical development.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.